Intelligence Augmentation Platform

Where papers meet proteins. Where teams move faster.

doi.bio unifies AI-powered literature synthesis with interactive molecular context. Structural biologists cut onboarding time in half and make structurally-aware decisions with confidence.

200M+
AlphaFold Structures
243K+
PDB Entries
50%
Faster Onboarding
The Challenge

Discovery teams juggle fragmented tools

R&D lives in two places—papers and proteins—but today's tools don't connect them

📄

Scattered Knowledge

PDFs, notes, and wikis rarely converge into reusable institutional memory. Scientists spend hours re-synthesizing context.

Manual synthesis Lost rationale Slow ramp
🧬

Disconnected Structure

Molecular viewers exist in isolation, forcing scientists to context-switch between literature insights and 3D analysis.

No shared state Missed clashes Wasted cycles
⚙️

Opaque Automation

Scripts and pipelines run without capturing reasoning, creating compliance headaches and repeated mistakes.

Hard to audit Limited reuse Slow debugging
The Platform

One workspace orchestrating context and compute

doi.bio blends AI literature synthesis, interactive molecular context, and guided workflows into a single collaborative surface.

🔗

Knowledge Graph

AI extracts targets, ligands, and assays from papers—building an interlinked graph that stays synced with 3D structures.

🧪

Live Molecular Context

PDB and AlphaFold structures load instantly, with pocket annotation, clash detection, and conservation analysis built in.

Workflow Automation

Trigger docking, MD, or custom compute with one click—results flow back into the narrative with full provenance.

👥

Team Collaboration

Decisions, rationales, and experiments become shared IP. New scientists inherit the full context in hours, not weeks.

Market Opportunity

Multi-billion dollar tailwinds

AI-enabled discovery is accelerating, and structural biology is at the center

$20B+
AI Drug Discovery Market by 2030
~30% CAGR
$95B+
Bioinformatics by 2032
17% CAGR
$2.23B
Avg R&D cost per drug
Every month counts

Who We Serve

Structural biologists, computational chemists, medicinal chemists in pharma, biotech, CROs, and academic labs

Immediate ROI

Days → hours for target triage. 50%+ faster onboarding. Fewer dead-end designs through early structural alerts.

Why Now

AlphaFold opened the floodgates. Teams need tools to operationalize 200M+ predictions—not just view them.

Leadership

Deep domain expertise meets technical excellence

SN

Steven Randolph Ness

Founder & CEO

Structural biochemist with ML PhD and decades of Linux/software experience. Deep expertise in PDB/AlphaFold ecosystems, molecular visualization, and AI-assisted research tools.

Structural Biology Machine Learning Molecular Viz AI Research
🎯

Advisory Board

In Development

Assembling leaders across medicinal chemistry, platform engineering, business development, and regulatory strategy to accelerate delivery and market fit.

Med Chem Platform Eng BD Strategy Regulatory